eligibility_summary
Eligibility: age 5–60, newly diagnosed, untreated classic HL stage I–II with measurable disease, PET ≤42 days, peds mediastinal CXR if suspected, performance Lansky ≥50 or Zubrod 0–2, adequate renal/hepatic, cardiac EF ≥50% or SF ≥27%, pulmonary DLCO ≥50% or O2 sat >92%, controlled HIV/HBV/HCV allowed. Exclude NLPHL, interstitial lung disease, uncontrolled illness, significant immunosuppression, neuropathy >1, prior cHL therapy/transplant, recent live vaccine, pregnancy/lactation, contraception and consent required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized phase 3 PET-adapted trial in stage I–II classical Hodgkin lymphoma comparing standard chemo±radiation vs immuno-oncology (brentuximab vedotin+nivolumab). Drugs/mechanisms: Brentuximab vedotin—anti-CD30 antibody–drug conjugate delivering MMAE (microtubule inhibitor) to CD30+ Reed–Sternberg cells. Nivolumab—PD-1 checkpoint inhibitor restoring antitumor T-cell activity. Chemo backbones: ABVD (doxorubicin—DNA intercalation/topo II, bleomycin—DNA breaks, vinblastine—microtubule inhibition, dacarbazine—DNA methylating), AVD, eBEACOPP/eBPDac (adds cyclophosphamide—DNA crosslinks, etoposide—topo II, procarbazine/dacarbazine—alkylating, vincristine—microtubule, prednisone—corticosteroid). ISRT adds DNA-damaging ionizing radiation. Targets/pathways: CD30 on HL cells, PD-1/PD-L1 on T cells, DNA damage/repair and microtubules in proliferating lymphoma cells.